Abstract:Objective To investigate the remission rate of acute myeloid leukemia (AML) patients after treatment with homoharringtonine (HHT)-based chemotherapy and evaluate the influence of karyotype and genetic mutation on overall survival (OS) and event free survival (EFS).Methods 80 de novo AML during Jan 2008 and Apr 2010 were collected.These patients were randomized into HAA,HDA,DA,IA,and were compared on complete remission (CR).They were also grouped as "good,median,bad" karyotype and also compared on OS and EFS until Feb 2013.In the meantime,the combined effects of karyotype and gene mutation on OS and EFS were also analyzed.Results 46 cases were treated by HHT-based induction therapy,in which CR rate was 78.3 ％ (36/46) and higher than 66.7 ％ (10/15) of DA and 63.2 ％ (12/19) of IA.But there was no difference between different groups (P ＞ 0.05).However,karyotype imposed great effect on OR in that the worse type had lower OS and EFS.And this trend was even more obvious when considering combination of karyotype and genotype.Conclusions HHT-based induction therapy has similar CR with DA and IA in treating AMLc,which indicating that homoharringtonine is very effective chemotherapeutic agent for AML.In addition,karyotype and genotype have greater effect on prognosis of AML after HHT-based chemotherapy.

Prognosis and Efficacy of Homoharringtonine-Based Chemotherapy on 46 De Novo Acute Myeloid Leukemia Patients